All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Twist Bioscience FY26 net loss widens 68% year over year to $130.2 million; FY26 revenue rises 22% year over year to $459.4 million

By Public Technologies
  • Twist Bioscience's Q4 FY26 net loss narrowed 24% year-over-year to $20.6 million; revenue rose 28% to $126.6 million.
  • FY26 net loss widened 68% year-over-year to $130.2 million; revenue climbed 22% to $459.4 million.
  • Cash, cash equivalents and short-term investments totaled approximately $582 million at September 30, 2026, following approximately $425 million in equity proceeds.
  • New launches included Twist Express Screening Antibodies and Twist MRD Express custom panels, offering turnaround times of as little as one day.
  • FY27 revenue guidance targets $550 million to $560 million, with first-quarter revenue projected at $130 million to $132 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000053), on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.